WallStreetZenWallStreetZen

NYSE: HAE
Haemonetics Corp Earnings Dates, Reports, Calls

OverviewForecastEarnings
RevenueDividendOwnership
Haemonetics earnings were $96.3M for the trailing 12 months ending Jun 27, 2026, with -36.5% growth year over year. The latest HAE earnings report on Jun 27, 2026 announced Q2 2026 earnings of $33.0M, down 263.8% from last quarter. For the last reported fiscal year 2026 ending Mar 28, 2026, HAE reported annual earnings of $97.3M, with -42% growth. The next HAE earnings date is Nov 5, 2026.

HAE past earnings growth

How has HAE's earnings growth performed historically?

Company
-36.47%
Industry
3.42%
Market
91.88%
HAE's earnings have grown faster... subscribe to Premium to read more.
Earnings Growth vs Industry Performance
HAE's earnings have grown slower... subscribe to Premium to read more.
Earnings Growth vs Market Performance
HAE's earnings growth is slowing... subscribe to Premium to read more.
Accelerating Earnings Growth Performance

HAE earnings history

Current Revenue
$1.4B
Current Earnings
$96.3M
Current Profit Margin
7.1%

HAE Return on Equity

Current Company
11.3%
Current Industry
8.8%
Current Market
30.9%
HAE's Return on Equity (11.3%)... subscribe to Premium to read more.
High Return on Equity Performance

HAE Return on Assets

Current Company
4%
Current Industry
7.3%
HAE is generating lower Return... subscribe to Premium to read more.
Above Average Return on Assets Performance

Be the first to know when HAE announces earnings.

HAE Return on Capital Employed

Current Company
7.63%
Current Industry
11%
HAE's ability to generate Return... subscribe to Premium to read more.
Increasing Return on Capital Employed Performance

HAE vs Medical Stocks

TickerEBITDAEarningsY/Y EarningsEPS
HAE$270.39M$96.29M+10.48%$2.09
MMSI$362.11M$145.56M+36.34%$2.45
TFX-$803.95M-$1.03BN/A-$23.28
ICUI$289.18M$30.09M-24.53%$1.20
NVST$420.80M$95.00M-20.94%$0.59
View Top Medical Stocks

HAE earnings dates

Next earnings date
Nov 5, 2026

Haemonetics Earnings Reports & History FAQ

What were Haemonetics's earnings last quarter?

On HAE's earnings call on Aug 6, 2026, Haemonetics (NYSE: HAE) reported Q2 2026 earnings per share (EPS) of $0.73, up 2.82% year over year. Total HAE earnings for the quarter were $33.01 million. In the same quarter last year, Haemonetics's earnings per share (EPS) was $0.71.

If you're new to stock investing, here's how to buy Haemonetics stock.

When does Haemonetics report earnings?

The next HAE earnings call is Nov 5, 2026. Add HAE to your watchlist to be reminded of Haemonetics's next earnings date.

Is Haemonetics profitable or losing money?

As of the last Haemonetics earnings report, Haemonetics is currently profitable. Haemonetics's net profit (also called net income) for the twelve months ending Jun 27, 2026 was $96.29 million, a 41.05% decrease year over year.

What was HAE's earnings growth in the past year?

As of Haemonetics's earnings date in Aug 6, 2026, Haemonetics's earnings has grown -36.47% year over year. This is 39.9 percentage points lower than the US Medical Instruments & Supplies industry earnings growth rate of 3.42%. HAE earnings in the past year totalled $96.29 million.

What are Haemonetics's earnings expectations?

The current EPS estimate for Haemonetics's earnings report in Nov 5, 2026 is $1.30.
©2026 WallStreetZen
Company
AboutNewsBlogStock Investing FAQPlansPrivacy PolicyTerms of ServiceCancellation & RefundsPerformanceHelp GuidesContactTwitterYouTubeNewsletter
Stock Tools
Top Performing AnalystsStock ScreenerStock ForecastTrending StocksStrong Buy StocksHighest Earnings StocksBest Dividend Paying StocksStatisticsStock Market SectorsStock Market IndustriesHow to Buy Stocks Online
Stock Ideas
Buy The DipBiggest Stock Gainers TodayBiggest Stock Losers Today52 Week High Stocks52 Week Low StocksMost Active Stocks TodayMost Undervalued StocksBest Penny Stocks to Buy NowBest Stocks Under $5Best Stocks Under $10
WallStreetZen does not provide financial advice and does not issue recommendations or offers to buy stock or sell any security.

Information is provided 'as-is' and solely for informational purposes and is not advice. WallStreetZen does not bear any responsibility for any losses or damage that may occur as a result of reliance on this data.